FCGR3A and rheumatoid arthritis: Early-RA patients were not significantly different than healthy controls in percentages of CD16 positive CD14++ monocytes, but were significantly different from long-standing RA patients (p = 0.22 and 0.008 respectively; Fig. 1D).